Stockscreener 앱 받기
13.02
3.63%
-0.49
시간 외 거래:
13.02
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus.com
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus.com
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - Marketscreener.com
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
(ETON) On The My Stocks Page - Stock Traders Daily
Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India
Eton Pharma rises on study results for rare disease drug - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com India
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Trading (ETON) With Integrated Risk Controls - Stock Traders Daily
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - GlobeNewswire
How Will Eton's Rare Disease Acquisitions Impact Future Growth? Investor Day Set to Reveal Strategy - StockTitan
Eton Pharmaceuticals Launches Galzin Capsules for Wilson Disease Treatment -March 03, 2025 at 11:48 am EST - Marketscreener.com
Eton Pharmaceuticals launches FDA-approved Wilson disease treatment - Investing.com
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules - GlobeNewswire
Only FDA-Approved Zinc Treatment for Wilson Disease Now AvailableWhat Makes Galzin Different? - StockTitan
60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Anchor Capital Advisors LLC - MarketBeat
(ETON) Trading Report - Stock Traders Daily
Acuitas Investments LLC Has $2.48 Million Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
Insider Buying: Opaleye Management Inc., Eton Pharmaceuticals Inc [ETON] 10% Owner invested 10,000 shares - Knox Daily
What Are You Thinking About Investing In Eton Pharmaceuticals Inc (NASDAQ: ETON) Stock? - Stocks Register
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going - MSN
Learn to Evaluate (ETON) using the Charts - Stock Traders Daily
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 - MSN
FDA extends target action date for Eton's ET-400 - MSN
Eton Pharmaceuticals Receives FDA Extension for NDA for ET-400On February 6, 2025, Eton Pharmaceuticals, Inc. announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUF - Defense World
3.70%
0.05%
자본화:
|
볼륨(24시간):